SCHEMBL12437775

SCHEMBL12437775

CC1CCCN(CCNC(=O)c2ccc(OC3CCN(Cc4ccc5c(c4)c4ccccc4n5C(C)C)CC3)c(Cl)c2)C1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 6/20 0.47
SLC5A7 Q9GZV3 1/20 0.46
CCR3 P51677 2/20 0.46
TP53 P04637 2/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
POLB P06746 1/20 0.40
RORC P51449 1/20 0.40
LMNA P02545 1/20 0.40
HTR1A P08908 1/20 0.39
CYP2D6 P10635 1/20 0.39
DRD2 P14416 1/20 0.39
HTR1D P28221 1/20 0.39
HTR2C P28335 1/20 0.39
HTR1F P30939 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
CYP3A43 Q9HB55 1/20 0.39
HTR7 P34969 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12437774 0.93 UTS2R (0.49) UTS2RSLC5A7CCR3TP53MAPT
SCHEMBL12513951 0.82 TP53 (0.46) UTS2RTP53MAPTSMN1; SMN2LMNA
SCHEMBL12437711 0.82 UTS2R (0.47) UTS2RCCR3TP53MAPTSMN1; SMN2
SCHEMBL12437896 0.82 UTS2R (0.44) UTS2RCCR3TP53POLBRORC
SCHEMBL12437773 0.81 UTS2R (0.45) UTS2RCCR3TP53SMN1; SMN2POLB
SCHEMBL12437769 0.81 HRH3 (0.47) TP53MAPTSMN1; SMN2HRH3RORC
SCHEMBL12437723 0.80 MAPT (0.51) UTS2RCCR3TP53MAPT
SCHEMBL12437702 0.80 MEN1 (0.47) UTS2RCCR3TP53MAPTDRD2
SCHEMBL12513928 0.79 TP53 (0.51) UTS2RSLC5A7CCR3TP53MAPT
SCHEMBL12437741 0.79 UTS2R (0.47) UTS2RCCR3TP53MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof AVALON PHARMACEUTICALS 2011-07-21 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof AVALON PHARMACEUTICALS 2009-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110178066-A1 Hydroxypiperidine derivatives and uses thereof HPGDS, HPGD, DPYD UTS2R 854/4885SLC5A7 4329/4885CCR3 2505/4885
US-20090036429-A1 Hydroxypiperidine Derivatives and Uses Thereof HPGDS, HPGD, DPYD UTS2R 854/4885SLC5A7 4329/4885CCR3 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.